Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

Milestone Pharmaceuticals Stock Down 60.9 %

Milestone Pharmaceuticals stock opened at $0.88 on Friday. The company has a 50 day moving average of $2.00 and a 200-day moving average of $1.83. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $2.75. The stock has a market capitalization of $46.95 million, a PE ratio of -1.09 and a beta of 1.83.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its position in shares of Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares during the period. National Bank of Canada FI lifted its stake in Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after acquiring an additional 11,600 shares in the last quarter. PVG Asset Management Corp acquired a new position in Milestone Pharmaceuticals during the 3rd quarter worth approximately $46,000. Cubist Systematic Strategies LLC bought a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth approximately $73,000. Finally, XTX Topco Ltd acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $80,000. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.